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Lydia Suchecki, fifth-year pharmacy student from Beavercreek, Ohio; Hannah Granger, fourth-year pharmacy student from 
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This knowledge-based activity is targeted for all pharmacists 
and is acceptable for 1.0 hour (0.1 CEU) of continuing 
education credit. This course requires completion 
of the program evaluation and at least a 70 percent grade 
on the program assessment questions. 
ACPE Universal Activity Number (UAN): 0048-0000-15-209-HO 1-P 
Objectives 
After completion of this program, the reader should be able 
to: 
1. 
2. 
3. 
4. 
5. 
Explain how benzodiazepines differentially affect the 
elderly population in terms of pharmacokinetics and 
pharmacodynamics. 
Discuss specific adverse effects of benzodiazepines 
in the elderly population and how these adverse ef-
fects impact quality of life. 
Identify patients who are at highest risk of adverse 
effects with benzodiazepine use. 
Describe symptoms of and possible treatments for 
patients experiencing withdrawal from benzodiaze-
pines. 
Identify ways a pharmacist can improve medication 
management in the elderly population. 
Abstract 
Benzodiazepines remain a commonly prescribed medication 
in the United States, and the high usage of this drug class is 
especially a concern in the elderly population for several rea-
sons. First, elderly patients metabolize drugs differently, 
leading to varying responses. A~e-related changes also have 
a significant impact on the effects of benzodiazepines. Sec-
ond, elderly patients are more likely to be taking multiple 
centrally-acting drugs, which can further exacerbate negative 
effects. In regard to long-term benzodiazepine use, elderly 
patients experience an increased risk of cognitive impair-
ment, motor vehicle accidents, decline in physical perfor-
mance, falls and subsequent fractures, and sleep disturbances. 
Withdrawal is also a significant concern with long-term ben-
zodiazepine treatment, which can lead to rebound symptoms 
in addition to mood swings, tremor, headache and loss of ap-
petite. A taper of less than six months is recommended when 
discontinuing benzodiazepines after use longer than the rec-
ommended three month duration of treatment. Pharmacists 
can have a substantial impact in reducing the detrimental 
effects of long-term use of benzodiazepines by aiding in the 
tapering process, as well as identifying inappropriate pre-
scribing and use of benzodiazepines in the elderly popula-
tion. Overall, pharmacists should be knowledgeable on the 
appropriate use of benzodiazepines, associated side effects 
and withdrawal concerns to reduce the negative effects 
elderly patients may experience with long-term use. 
Key Terms 
Accidental Falls; Aged; Benzodiazepines; Cognition; Hypnot-
ics and Sedatives; Pharmacists; Quality of Life 
Introduction 
Despite the potentially detrimental effects of benzodiazepine 
use, benzodiazepines remain a commonly prescribed medi-
cation in the United States. In 2012, Ohio prescribers wrote 
41.3 prescriptions for benzodiazepine medications per 100 
people, ranking Ohio 20th compared to other states.1 Ohio is 
slightly above the national rate of 37.6 prescriptions per 100 
people. The high usage of benzodiazepines is especially a 
concern in the elderly population, in part because elderly 
patients respond to and metabolize drugs differently. Even if 
a patient has been on a benzodiazepine for many years, it 
may begin to have different or more severe adverse effects as 
the patient ages. Elderly patients, generally defined as 65 
years of age and older, are also more likely to be taking sev-
eral medications, which may include other centrally-acting 
drugs. The combination of these factors leads to an increased 
risk of cognitive impairment, motor vehicle accidents, decline 
in physical performance, falls and subsequent fractures, and 
sleep disturbances in the elderly population. 
Benzodiazepines are included on the American Geriatric So-
ciety's Beers Criteria, which notes that elderly patients are 
known to have higher sensitivity to and slower metabolism 
of long-acting benzodiazepines, increasing the risk of nega-
tive effects.2 Studies have found these effects can also be seen 
with short-acting formulations .3 It can be concluded that if 
detrimental effects are seen with both short-acting and long-
acting formulations of benzodiazepines, then these effects 
can also be observed with the intermediate-acting medica-
tions (Table 1).4 The Beers Criteria recommendation for ben-
zodiazepine use is classified as 'strong,' meaning that the 
burdens/risks of use outweigh the potential benefits.2 Alt-
hough benzodiazepines may still be an appropriate option in 
some instances, per the Beers Criteria their use is not 
recommended in the elderly to treat insomnia, agitation or 
delirium. Discontinuation of this class of drugs has been as-
sociated with some improvement in their negative effects, 
especially those effects relating to cognition; however, there 
are still lasting implications with long-term use. The with-
drawal process and associated symptoms are also significant, 
owing to the addictive properties and dependency effects of 
this class of drugs.s As pharmacists, it is important to recog-
nize how these drugs may affect elderly patients differently 
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Table 1. Commonly Prescribed Benzodiazepines. 
Short-acting* Intermediate-acting* Long-acting* 
• Midazolam (Versed™) • Alprazolam (Xanax™) • Chlordiazepoxide (Librium TM) 
• Triazolam (Halcion™) • Conazepam (Klonopin ™) • Flurazepam (Dalmane™) 
• Diazepam (Valium™) 
• Lorazepam (Ativan™) 
• Oxazepam (Serax™) 
• Temazepam (RestorW"') 
*classification based on half-life of active components4 
and to manage these medications accordingly. Pharmacists 
have an essential role in identifying elderly patients being 
newly prescribed or currently taking long-term benzodiaze-
pines who may be candidates for other treatment options, 
making alternative medication recommendations to physi-
cians and assisting patients during the withdrawal process. 
Typical and appropriate indications for benzodiazepine use 
in the elderly include anxiety, panic disorder, sleep disorder 
and adjustment disorder which are similar to the indications 
for use in the nonelderly population. However, in some in-
stances such as in a patient who is refractory to standard 
treatment, benzodiazepines may be appropriately used for 
short-term treatment of insomnia or agitation even though 
the recommendation from the Beers Criteria is to avoid use 
for these indications.2 Central nervous system (CNS) depres-
sion is a typical side effect of benzodiazepines for all age 
groups. Of significance is that within the older population 
these side effects are observed more frequently and to a 
greater extent, and some negative outcomes such as falls, 
fractures and a decrease in physical performance are unique 
to the elderly demographic. In the elderly population, these 
side effects can have substantial implications on the patient's 
quality of life, autonomy and independence. This increased 
severity of side effects is due primarily to pharmacodynamic, 
rather than pharmacokinetic, changes in the CNS and brain 
that occur naturally with aging and lead to a greater sensitiv-
ity to benzodiazepines.6·7 In fact, elderly patients generally 
require lower doses of benzodiazepines, corresponding to 
lower blood concentrations to achieve the effect of sedation, 
highlighting the increased sensitivity displayed in older pa-
tients.a The pharmacokinetic changes that occur include 
changes in the elimination and distribution of benzodiaze-
pines in the aging brain; but, more importantly, the pharma-
codynamic changes in the CNS make the receptors more 
sensitive to the drug.7 The target for benzodiazepines to pro-
duce their CNS effects are the gamma-aminobutyric acid-a 
(GABAa) receptors, which are ligand-gated chloride chan-
nels. The binding of the benzodiazepine causes the channel 
to open and results in an influx of chloride, which decreases 
neuronal firing.9 The GABAa receptor is made up of several 
subunits, which contributes to why there are a variety of 
symptoms associated with this drug class in all patient age 
groups. The increase in severity of side effects in the elderly 
may be so extreme for benzodiazepines in particular because 
GABAa receptors are widely distributed throughout the CNS 
in the spinal cord, cortex, cerebellum, and limbic system, and 
the distribution of the GABAa receptors changes with age, 
altering the excitability of the brain.6,9 With the high number 
of receptors and an increased sensitivity with the aging pro-
cess, many of the effects seen in a younger person will be 
exaggerated in the elderly such as greater sedation, less coor-
dination of movement and less inhibition.7 Changes in psy-
chomotor abilities, reaction time, delirium, coordination and 
attention are also potential effects of benzodiazepine use in 
the elderly.10.11 
Cognitive Impairments 
The use of benzodiazepines can negatively impact cognition 
or exacerbate normal age-related cognitive decline in elderly 
patients. However, the length of time the patient is taking the 
medication is a significant predictor of cognitive decline.12 
Associated risks are increased with the long-term use of ben-
zodiazepines even in those patients who used benzodiaze-
pines chronically and have already successfully discontinued 
therapy. The length of time a patient has been taking benzo-
diazepines is a significant predictor of cognitive decline and 
has been shown to have a greater effect on sustained cogni-
tive impairment compared to the dose alone. Evidence sup-
porting the long-term implications on cognition is varied. 
Not all patients taking therapeutic doses of benzodiazepines 
long-term will experience these cognitive and memory im-
pairing effects, or the effects they do experience may be mini-
mal.12·13 However, several studies have found that cognitive 
impairment does occur with chronic benzodiazepine use.10 
Central nervous system depression and decline in cognition, 
alertness and decision-making capacity are all recognized 
side effects of therapy. Notable short-term effects include 
anterograde amnesia, or difficulty learning new information, 
a decrease in mental alertness and the capacity to coordinate 
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fine movements.13 Long-term users tend to develop some 
tolerance to the sedative effects (for example, the drowsiness 
is less severe over time when compared to initiation of thera-
py), but effects on memory and cognition continue through-
out use. Patients taking benzodiazepines chronically may 
also struggle to process information quickly and sustain at-
tention on a task for an extended amount of time, as well as 
have difficulty with visuospatial skills. These effects are more 
detrimental in the elderly population in terms of severity and 
persistence of symptoms, even after the medication has been 
discontinued. These negative cognitive effects impact the 
elderly patient's quality of life, memory and independence. 
The negative effects of benzodiazepine use in the elderly may 
extend beyond the duration of therapy to a greater extent 
than in the nonelderly population. Cognitive impairment was 
found to persist for at least six months after discontinuation, 
in comparison to patients who had not been on benzodiaze-
pines, suggesting that this class of drugs may cause function-
al changes in the brain that are permanent or at least slowly 
reversible.10 While there is strong evidence that benzodiaze-
pines have negative effects on cognitive performance while 
using the medication, not all studies support the same 
conclusion, and research is inconclusive as to how long the 
damage lasts once the medication is discontinued. A meta-
analysis involving 13 studies that lasted for a t least one year 
and were published between 1980 and 2000 examined the 
effects of long-term benzodiazepine use on cognition.5 The 
authors were not able to make conclusions about whether or 
not the cognition and memory impairment of benzodiaze-
pines extended beyond therapy termination due to the heter-
ogeneity and limited number of studies in the meta-analysis. 
The study points to the complicated nature of assessing 
cognition considering the impact of test-induced anxiety in 
patients who may already be prone to anxiety. In practice, 
however, the most conservative treatment plan should be 
used if possible; the potential risk of lingering CNS effects 
impacting cognition is high enough to discourage long-term 
use of benzodiazepines if another treatment of equal efficacy 
is available. 
Motor Vehicle Accidents 
Decreased alertness, altered decision-making capacity and 
changes in perception are cognitive-based factors that con-
tribute to an increased risk of motor vehicle accidents in el-
derly patients taking benzodiazepines.14,15 Reaction time is 
another critical factor that is negatively impacted by benzo-
diazepine use.14 Crashes that involve elderly drivers are gen-
erally related to perception and cognitive difficulties, such as 
crossing the center into the adjacent lane, inappropriate 
judgment of gaps between vehicles and not giving way to 
other vehicles. Although studies still show that younger driv-
ers are more likely to be in car accidents than older drivers, 
the risks are highest in those ages 18 to 25 years and ages 65 
years and greater.14,15 Importantly, in the 65 years of age and 
greater population, there is an even higher risk of accidents 
in those taking benzodiazepines.14 In fact, benzodiazepines 
are commonly found at detectable blood levels in people in-
volved in car accidents when it is suspected that they were 
impaired due to substances. This finding includes both ben-
zodiazepines being used therapeutically and as drugs of 
abuse, meaning it includes those taking benzodiazepines for 
reasons other than prescribed or at doses higher than pre-
scribed. As expected, the risks associated with benzodiaze-
pines and traffic accidents increase with the size of the dose, 
the number of benzodiazepines being used, combinations 
with other CNS depressants (e.g., alcohol) and how long the 
driver has been taking the medication. This may even sug-
gest that tolerance develops to the side effects of the medica-
tion with chronic use compared to the cognitive changes 
seen initially in a patient on a benzodiazepine.16 
Physical Disability 
Benzodiazepines increase the risk for mobility impairments 
and difficulties with completing daily tasks such as bathing, 
dressing and feeding.3,17 The decline in physical performance 
is due to the effects on the patient's neuromuscular pro-
cessing and psychomotor abilities, as well as the sedation, 
that is caused by benzodiazepine use.3 Again, there is some 
natural risk of declining mobility and ability to perform daily 
tasks associated with aging, but benzodiazepine use in the 
elderly has been found to increase the risk for physical disa-
bility by 23 percent. Specifically, women are at a greater risk 
for these changes than elderly men likely due to poorer mus-
cle strength and control initially.J.17 Although it was previ-
ously believed that these physical impairments would be 
lessened if the patient was prescribed short-acting rather 
than long-acting formulations due to the shorter half-life, not 
all studies support this theory.3 Short-acting benzodiaze-
pines are more likely to be taken in higher doses, therefore 
increasing total drug exposure and leading to higher peak 
concentrations. Overall, risk for physical disability is greatest 
in patients using higher doses and long-term therapy, de-
fined as three years or more in this study specifically.17 Un-
fortunately, the negative effects on physical functioning can 
still be seen even at low doses of benzodiazepines.3 Although 
higher drug exposure does tend to lead to more detrimental 
effects, there are still many interindividual differences that 
allow low doses to have an equally negative impact in some 
patients. One study examined whether the physical disability 
was resulting from benzodiazepine use itself or from a shift 
to a less active lifestyle due to the sedative effects of the 
medication. It was concluded that activity level was not a 
confounder in decreasing physical performance, so it can be 
concluded that the effects of the benzodiazepine were likely 
the reason for the decline in physical function. 
Fall Risks 
Benzodiazepines are one of many drug classes that pose a fall 
risk in the elderly population owing to an increase in the 
risks associated with falls, such as impaired muscle strength, 
coordination and balance. Although risk of falls increases 
naturally with aging, benzodiazepine use can exacerbate this 
risk. In a study, handgrip strength and balance were used as 
indicators to assess fall risk in elderly patients taking the 
intermediate-acting benzodiazepine, temazepam, or one of 
two Z-drugs, zolpidem or zolpiclone, which work similarly to 
benzodiazepines.1s Successful discontinuation from long-
term benzodiazepine use led to an improvement in handgrip 
strength and balance in elderly patients. The findings showed 
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that benzodiazepine usage does play a significant role in fall 
risk, and the incidence among some elderly patients may be 
due to more than typical age-related decline. This fact in-
creases the importance of identifying patients who could be 
switched to an alternate therapy. As women are at a greater 
risk of physical disability than men, as noted earlier, this also 
places them at a greater risk for falls than men. Considering 
overall health care economics, benzodiazepines are relatively 
inexpensive medications, but the financial burden of treating 
falls and fall-related injuries attributed to benzodiazepine 
use can be significant. 
Fractures 
In the elderly population, fractures and other musculoskele-
tal injuries are often sustained due to falls. As expected, there 
is an increase in fractures in long-term benzodiazepine us-
ers.19 Similar to the research regarding physical disability in 
general, there was not a difference in fractures sustained due 
to benzodiazepines based on whether they were short-acting 
or long-acting products.3,19 In a study that compared the 
United States with several large European countries, the 
overall average of hip fractures that could be attributed, at 
least in part, to benzodiazepine use was 1.8 to 8.2 percent.19 
Although this is a large range, even the most conservative 
finding of 1.8 percent shows that fractures as a consequence 
of benzodiazepine use are still meaningful when considering 
the other age-related and drug-related causes for fractures 
and falls in the elderly population and the individual impact a 
fracture has on a patient's quality of life. 
Sleep Problems 
Sleep disturbances are a frequent reason for an elderly pa-
tient to be prescribed a benzodiazepine, yet approximately 
80 percent of the elderly population who are taking benzodi-
azepines report having problems with sleep.zo.z1 Despite the 
indication for benzodiazepines to help with sleep, a study 
found that overall sleep quality declined in adults 65 years of 
age or older when using benzodiazepines long-term.zo 
Though these medications are generally only recommended 
to be used for three months, regardless of age and indication, 
most patients use them for much longer. Another meta-
analysis that examined 45 randomized controlled trials test-
ing benzodiazepine use for insomnia found that although 
benzodiazepines are slightly beneficial in increasing the 
length of time a patient is asleep, there are not any significant 
benefits on the length of time for sleep onset, and there are 
additional negative effects associated with their use.z1 The 
most common negative effects patients reported in the stud-
ies included being drowsy during the day, dizziness and 
lightheadedness. For long-term users of benzodiazepines, the 
risks and negative effects associated with usage outweigh the 
potential benefit for sleep. 
Like most of the effects discussed previously, sleep disturb-
ances are seen more significantly in the elderly population 
due to the negative impacts of benzodiazepine use being 
compounded with natural, age-related decline in sleep quali-
ty.zo Importantly, not only did the benzodiazepine users have 
poorer sleep quality than nonusers, but those taking benzo-
diazepines long-term had the worst sleep quality overall 
when compared to those who only took the medications 
short-term. This result is not often seen in initial clinical tri-
als assessing medications' effects on sleep because research 
is often not conducted for a long enough time to appropriate-
ly examine the effects of the drug long-term, which is how 
the drugs are often used in practice. 
Withdrawal 
Although cognitive impairment, physical disabilities and 
sleep problems are possible adverse effects of taking benzo-
diazepines, withdrawal is perhaps the biggest controversy 
pertaining to their use. However, due to prescribing tradi-
tions and patient preference, long-term use of benzodiaze-
pines occurs in more than one-third of patients.zz-z4 This is a 
cause for alarm due to the risks of adverse effects and contin-
ued efficacy. A study by Salzman and colleagues found the 
memory and cognitive functioning of elderly nursing home 
patients improved in those tapered off benzodiazepines 
when compared to those who remained on the medica-
tions.zs The recommendation for those patients on benzodi-
azepines for longer than three months is to gradually reduce 
the dosage through a tapering schedule.z6 This taper should 
last less than six months or else this process occupies all of 
the patient's focus.zs Before interrupting benzodiazepine use, 
health care providers should ensure the patient is in good 
health, and that he or she is fully educated about the possible 
recurrent, rebound or new symptoms that can occur.zz.z7 
The original indication for benzodiazepine use, whether in-
somnia or anxiety, may worsen to pretreatment levels during 
the tapering period.Z4 In some cases, the symptoms may ele-
vate beyond pretreatment levels and is considered a rebound 
symptom. Therefore, it is necessary to evaluate the patient's 
underlying medical or psychiatric conditions before ceasing 
benzodiazepine use.zz Symptoms of withdrawal and rebound 
are enhanced with the use of short-acting benzodiazepines 
due to their short half-life, rapid elimination and increased 
dosing frequency (Table 1).Z4 The short-acting agents, mid-
azolam and triazolam, are generally not used throughout the 
day, so the withdrawal and rebound may not be as evident, 
although rebound effects have been reported with the use of 
triazolam.zs Alprazolam and oxazepam, which are considered 
intermediate-acting agents with half-lives of about three to 
20 hours, may be dosed more frequently and are associated 
with symptoms of withdrawal and rebound if discontinued 
abruptly. z7 Rebound symptoms may occur after long-term 
use of any benzodiazepine, and may require a nonbenzodiaz-
epine substitute for those experiencing exacerbations of 
their sleep disorders or anxiety. Selective serotonin reuptake 
inhibitors (SSRls) or tricyclic antidepressants (TCAs) are 
acceptable alternatives for those with rebound depressive 
symptoms, and melatonin agonists, such as ramelteon 
(Rozerem®), may aid in sleep disorders.nzs.z9,30 Psychologi-
cal support, spanning from encouragement to cognitive or 
behavioral therapy, should also be provided for those 
patients in need of anxiety management and should be 
available long after tapering is complete.z3 Decreased use of 
caffeine and alcohol, along with proper sleep, hygiene and 
relaxation techniques, may be enough to help insomnia with-
out the need to initiate medications. Overall, the entire health 
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care team needs to be prepared to help the patient pharma-
cologically and nonpharmacologically with any issues result-
ing from rebound symptoms throughout tapering. 
Along with possible rebound symptoms, withdrawal 
symptoms add to the difficulty of the benzodiazepine taper-
ing process. The most frequent withdrawal symptoms in-
clude insomnia, anxiety, mood swings, myalgia/muscle 
twitching, tremor, headache, nausea/vomiting, loss of appe-
tite, hypersensitivity to noise, changes in movement and feel-
ings of unreality.29 Throughout the withdrawal process these 
symptoms wax and wane and can differ in severity for each 
patient.23 The 20-item Benzodiazepine Withdrawal Symptom 
Questionnaire or the Physician Withdrawal Checklist can be 
used to measure patient's symptoms during each case of 
withdrawal.31 Due to these occasionally unbearable symp-
toms, slow dosage reduction and proficient psychological 
support are necessary for the success of benzodiazepine ta-
pering.23 Abrupt withdrawal could cause convulsions, panic 
reactions and acute psychotic states. The occurrence of sei-
zures upon withdrawal, although rare, is more likely in pa-
tients with an underlying seizure disorder or when receiving 
concomitant medications that may lower the seizure thresh-
old.27 As previously mentioned, tapers should last less than 
six months, but this process should be adapted to each indi-
vidual patient based on lifestyle, personality, environment 
and available support. 23,2s 
Dosage reduction is an individualized process based on each 
patient's characteristics.23 Those on higher doses of benzodi-
azepines can tolerate larger dosage cutbacks, and the 
majority of patients take therapeutic doses less than 20 mg 
diazepam or equivalent daily. The usual dose of diazepam for 
the treatment of anxiety is 2 mg to 10 mg two to four times 
daily if needed, allowing for a maximum dose per day of 40 
mg.32 Generally, it is recommended to reduce the dose by 10 
percent to 25 percent each week.22 Reductions of 1 mg diaze-
Table 2. Benzodiazepine Equivalent Doses.22,23,27 
Benzodiazepines 
Alprazolam (Xanax) 
Chlordiazepoxide(Librium) 
Clonazepam (Klonopin) 
Clorazepate (Tranxene) 
Diazepam (Valium) 
Flurazepam (Dalmane) 
Lorazepam (Ativan) 
Oxazepam (Serax) 
Quazepam (Doral) 
Temazepam (Restoril) 
Triazolam (Halcion) 
pam every one to two weeks are usually well tolerated.22 Yet, 
if the patient is taking 40 mg of diazepam daily, an initial re-
duction of 2 mg every one to two weeks may be more appro-
priate, as the patient is considered to be on a higher dose. 
Once the daily dosage reaches 4 mg to 5 mg, decreasing by 
0.5 mg may be preferred to prevent negative effects. In order 
to improve adherence and patient's peace of mind, a written 
withdrawal schedule should be provided rather than just 
verbal instructions. A chart to check off days and doses is 
helpful for patients to stay goal-oriented. These schedules 
will be flexible to changes upon the appearance of any prob-
lems, such as severe symptoms or stressors. If at any point in 
the process withdrawal symptoms become notably severe, 
the tapering can be slowed. Diazepam, an intermediate-
acting agent, is the easiest benzodiazepine for tapering since 
it has multiple available strengths including 10 mg, 5 mg and 
2 mg tablets. Therefore, many patients are switched from 
their original benzodiazepine medication to an equivalent 
diazepam dosage (Table 2) especially within one month of 
complete discontinuation.22.23,27 Keep in mind, psychological 
and anxiety management should be provided throughout the 
entire dosage reduction process. 
Benzodiazepine withdrawal is a very complex and taxing 
process for patients. As a result, it is recommended any pa-
tient dependent on benzodiazepines and going through with-
drawal attends self-help groups run by ex-benzodiazepine 
users, psychologists, counselors or trained paramedical 
workers .23 Along with these group meetings, it is important 
for the patients to receive individualized psychological care 
in which they can confront personal or social problems un-
derlying their anxiety and need for long-term benzodiaze-
pine use. Involvement of family members in this practice is 
significant because it allows the patient to feel supported and 
to expose themselves to others, which increases their confi-
dence and self-esteem. These individuals need to be highly 
self-motivated in order to succeed with the tapering regi-
Oral Doses (mg) Equivalent to 10 mg Diazepam 
0.5 -1 
25 
0.5 
15 
10 
30 
1-2 
20 
20 
20 
0.25 - 0.5 
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mens. As stated earlier, it is important to inform patients of 
the possible problems that can occur during withdrawal and 
ensure they are dedicated and willing to fully adhere to the 
program. Health care providers for any patients going 
through withdrawal or abusing benzodiazepines can educate 
them regarding the advantages of withdrawal and establish 
trust with them each step of the way. 
Even though psychological support is available to patients 
throughout benzodiazepine tapering, the withdrawal symp-
toms may be perceived as too difficult to handle. Several 
medications have been evaluated as possible withdrawal and 
symptom-relief aids in order to allow more patients to be 
successful. Flumazenil is a benzodiazepine partial agonist 
which normalizes receptor function and has been evaluated 
for decreasing patients' craving and relapse rates and even 
reducing the hostile and aggressive behaviors that are often 
associated with withdrawal.33.34 A randomized, placebo-
controlled study found that when compared to oxazepam, 
flumazenil can counteract benzodiazepine effects and control 
benzodiazepine withdrawaJ.33 Topiramate and carbamaze-
pine, both anticonvulsants, have also been investigated in the 
treatment of withdrawal symptoms and possibly relapse pre-
vention.ls However, none of these medications have been 
found to be fully successful in preventing benzodiazepine 
withdrawal. 
Role of the Pharmacist 
Long-term use of benzodiazepines can lead to many adverse 
effects, cognition issues and withdrawal symptoms. As one of 
the most accessible health care providers, pharmacists can 
have significant impact by aiding patients throughout this 
complicated and difficult process. First, pharmacists in all 
institutions and fields of pharmacy can identify elderly pa-
tients taking long-term benzodiazepines and use their pro-
fessional judgment and knowledge to evaluate if the benefits 
outweigh the risks for each individual patient. Community 
pharmacists can assist in drug adherence and patient educa-
tion by identifying potential drug interactions or adverse 
reactions, supplying weekly pill dispensers or other compli-
ance aids and administering information about specific 
drugs.36 However, the pharmacist's responsibility expands 
far beyond the patient. Pharmacists are in a good position to 
communicate with prescribers in both the inpatient and 
community settings to determine if patients could be 
switched to another less risky therapy to treat their condi-
tion. Also, pharmacists should educate other health care pro-
fessionals and ensure benzodiazepines are being prescribed 
only for appropriate conditions when other options are not 
available. Additionally, information should be exchanged 
between pharmacists and physicians about medication re-
views, prescribing committees, compiling drug formularies, 
dose reduction regimens and possible ways to deal with ben-
zodiazepine withdrawal. 
Conclusion 
Benzodiazepines are a commonly prescribed class of 
medications in the elderly for anxiety and insomnia. Howev-
er, long-term use of this class of medications is associated 
with detrimental effects including cognitive impairment, 
sleep disturbances and physical disabilities. These drug-
associated effects can lead to an increase in motor vehicle 
accidents in the elderly patient population as well as an in-
creased fall risk leading to more fractures and a decreased 
quality of life. Withdrawal is one of the greatest issues with 
Jong-term benzodiazepine treatment which can lead to re-
bound symptoms plus mood swings, tremor, headache, loss 
of appetite and more. A taper of less than six months is rec-
ommended when discontinuing long-term benzodiazepine 
use. Pharmacists can be beneficial during the tapering pro-
cess, but also have the professional responsibility to identify 
inappropriate prescribing and use of benzodiazepines in the 
elderly population, which could circumvent many of these 
issues altogether. Overall, the continued use of benzodiaze-
pines in this patient population requires pharmacists to stay 
updated on appropriate indications, side effects and with-
drawal concerns as well as educate other health care profes-
sionals when necessary. 
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Assessment Questions 
l. Why is the high usage of benzodiazepines especially a 
concern in the elderly population? 
A. Elderly patients respond to and metabolize 
benzodiazepines differently. 
B. Elderly patients are more likely to be taking 
multiple medications, which may include other 
centrally-acting ones. 
C. Benzodiazepines, as a class, are more expensive 
compared to other medications with similar 
indications. 
D. Two of the above are correct. 
2. According to the Beers Criteria, which is not a recom-
mended indication for benzodiazepine use in elderly 
patients? 
A. insomnia 
B. anxiety 
C. panic disorder 
D. Two of the above are correct. 
3. The increase in the severity of negative side effects with 
benzodiazepine use in the elderly population is primarily 
because of _ _ changes. 
A. pharmacokinetic 
B. pharmacogenomic 
C. pharmacodynamic 
D. pharmacoeconomic 
4. When considering the impact of benzodiazepines on 
cognition, which is true? 
A. Negative effects may extend beyond the 
duration of therapy. 
B. Dose is a greater predictor of negative cognitive 
effects than the length of therapy. 
C. Both A and Bare correct. 
D. Neither statement is correct. 
5. In regard to benzodiazepines and physical function, 
which is true? 
A. Women are at a higher risk to suffer from a 
decline in physical function and fractures. 
B. Negative effects on physical function are not 
seen with short-acting benzodiazepines. 
C. The sedative effects of benzodiazepines de-
crease the activity level and lead to a decline in 
physical function. 
D. Two of the above are true. 
6. Although typically used much longer, the recommended 
length of time for using benzodiazepines is ___ _ 
A. Six weeks 
B. Three months 
C. No more than one year 
D. There is no recommended length of time; 
long-term use needs to be monitored. 
7. When considering the impact of benzodiazepine use on 
motor vehicle accidents, which is true? 
A. Benzodiazepines can have detrimental impacts 
on driving only when used abusively. 
B. Due to benzodiazepine use (along with other 
sedative substances), elderly drivers are the 
most likely to be involved in a motor vehicle 
accident compared to other drivers. 
C. Benzodiazepine use can impair reaction time 
and alertness of an elderly driver. 
D. Benzodiazepines have not been found to have a 
significant impact on motor vehicle accidents. 
8. The taper schedule for benzodiazepines should be no 
longer than: 
A. Two months 
B. Four months 
C. Six months 
D. One year 
9. In regard to the tapering process, the recommended dos-
age reduction ofbenzodiazepines per week is: 
A. 10-25% 
B. 5-10% 
c. 25-30% 
D. 15-35% 
10. The benzodiazepine partial agonist that has been evalu-
ated for decreasing patient's craving and relapse rates, 
normalizing benzodiazepine receptor function and even 
reducing hostile and aggressive behavior often associat-
ed with withdrawal is: 
A. oxazepam 
B. topiramate 
C. carbamazepine 
D. flumazenil 
[i!i], Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This 
program is eligible for credit until 5/2l/201 8. 
To receive continuing education credit for this program, you 
must answer the above questions and fill out the evaluation 
form. Please visit www.raabecollegeofpharmacy.org/ PA W to 
enter the required information. Please allow two to three 
weeks for electronic distribution of your continuing educa-
tion certificate, which will be sent to your valid email address 
in PDF format. 
To receive continuing education credit for this program, visit www.raabecollegeofnharmacv.org/PA W OR fill out the 
form below including your indicated answers to the assessment questions and return to: 
Office of Continuing Education at The Raabe College of Pharmacy 
Ohio Northern Universitv 525 South Main Street Ada, Ohio 45810 
Program Title: The Effects of Long-Term Benzodiazepine Use and Withdrawal in the Elderly 
UAN: 0048-0000-15-209-HOl-P CEUs: 0.1 
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of continuing 
education credit. You MUST provide your CPE Monitor# and Month and Day of birth to receive credit. 
Name: 
---------- -------~----- -
Address: 
City: 
Phone: 
Check one: Pharmacist 0Technician D 
CPE Monitor #: 
The program objectives were clear. 
The program met the stated goals and objectives: 
State: 
Email: 
License#: 
Birthday (MM/DD): 
1. Explain how benzodiazepines differentially affect the elderly popula-
tion in terms of pharmacokinetics and pharmacodynamics. 
2. Discuss specific adverse effects of benzodiazepines in the elderly pop-
ulation and how these adverse effects impact quality of life. 
3. Identify patients who are at highest risk of adverse effects with ben-
zodiazepine use. 
4. Describe symptoms of and possible treatments for patients experi-
encing withdrawal from benzodiazepines. 
5. Identify ways a pharmacist can improve medication management in 
the elderly population. 
The program met your educational needs. 
Content of the program was interesting. 
Material presented was relevant to my practice. 
Audio/visual and/or printed materials aided the learning process. 
The program used effective teaching/learning methods. 
The learning assessment activities were appropriate. 
The program showed good objectivity and no commercial bias. 
Would you recommend this program to a colleague? 
What was the most valuable part of this program? 
Zip: 
State: 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
Based on what you have learned what one change do you plan to make in your practice? --- ----- ----
The speaker was well prepared and knowledgeable about the topic. 
The quality of the speaker was excellent. 
The speaker provided adequate time for questions. 
1 
1 
1 
2 
2 
2 
3 
3 
3 
4 
4 
4 
5 
5 
5 
Comments: - -------------------------------------------
Suggestion for future programs you would like to see: ---- - - --------------------
Answers to Assessment Questions-Please Circle Your Answer 
1.ABCD 
2. A B C D 
3. A B C D 5. A B C D 7. A B C D 9. A B C D 
4. A B C D 6. A B C D 8. A B C D 10. A B C D 
Any questions/comments regarding this continuing education program can 
be directed to Lauren Hamman, Advanced Administrative Assistant for 
the Office of Continuing Education (email: l-hamman@onu.edu, phone 
419-772-2280). m Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education provider of continuing pharmacy education. program is eligible for credit until 5/2 1/2018. as a This 
